ライフサイエンスコーパス: HLA-matched

1 lay a role in clinical BMT rejection that is HLA matched.

2 antation period was 79% (95% CI 74-85) after HLA matched, 76% (71-81) after one allele mismatched, 70

3 -cell grafts for adults in the absence of an HLA-matched adult donor.

4 ematopoietic stem cells for patients without HLA-matched adult donors.

5 s (PBPCs) or bone marrow, especially when an HLA-matched adult unrelated donor is not available.

6 ssigned to the remaining patients undergoing HLA-matched allo HCT (validation cohort; n = 577) as wel

7 portunity to optimize GvHD prophylaxis after HLA-matched alloBMT and increase the use of HLA-mismatch

8 prophylaxis of acute and chronic GvHD after HLA-matched alloBMT.

9 ve burden experienced by patients undergoing HLA-matched alloBMT.

10 ctivity of sequential infusions of partially HLA-matched allogeneic blood mononuclear cells (obtained

11 (GVHD) and graft-versus-leukemia effects in HLA-matched allogeneic blood or marrow transplantation (

12 nt were given one to six infusions of partly HLA-matched allogeneic EBV-specific cytotoxic T lymphocy

13 61 patients were enrolled, 42 were HLA matched and 19 were haploidentical.

14 Most donors were HLA matched and related (93%).

15 prognostic of outcome in patients undergoing HLA-matched and -mismatched allo HCT for MDS.

16 we genotyped donors and recipients from 209 HLA-matched and 239 mismatched T-replete URD transplanta

17 ukemia (CML), we investigated the ability of HLA-matched and mismatched CD56(+) cells to inhibit gran

18 IS drugs has been achieved in recipients of HLA-matched and mismatched living donor kidney transplan

19 dence interval 0.48-0.86; P = .003) for both HLA-matched and mismatched transplants.

20 These data support the use of HLA-matched and one- or two-antigen HLA-mismatched umbil

21 13% from HLA-mismatched relatives, 12% from HLA-matched, and 41% from HLA-mismatched unrelated donor

22 ntation of antigen to these T-cell clones by HLA-matched antigen-presenting cells exposed to the inta

23 transplants in these patients are routinely HLA matched, any immunization responsible for increased

24 unction, and an unrelated adult marrow donor HLA matched at the allele level for HLA A, B, C, and DRB

25 evaluate closely histocompatibility antigen (HLA)-matched banked antigen-specific T cells so that T-c

26 tineoplastic effects of irradiated partially HLA-matched blood mononuclear cells obtained from relati

27 d be considered an acceptable alternative to HLA-matched BM for pediatric patients.

28 ation are comparable to those observed after HLA-matched BM transplantation.

29 Because the optimal timing of HLA-matched BMT for MDS is unknown, we constructed a Mar

30 yields similar survivals to those seen with HLA-matched BMT.

31 titutional study of human leukocyte antigen (HLA) -matched bone marrow transplantation would provide

32 When successful, human leukocyte antigen (HLA)-matched bone marrow transplantation with reduced-in

33 that had one HLA mismatch (83 patients), and HLA-matched bone marrow (367 patients).

34 lable to most patients due to the lack of an HLA-matched bone marrow donor.

35 r many nonmalignant hematological disorders, HLA-matched bone marrow transplantation (BMT) is curativ

36 Thus CTL were advantageous when functionally HLA matched but for certain tumor types complete respons

37 GVHD after prophylactic CD4+ DLI after 10/10-HLA-matched, but HLA-DPB1-mismatched TCD-alloSCT.

38 ing of tumor-associated Ags and expressed by HLA-matched cancer cell lines.

39 y (TRM), and overall mortality compared with HLA-matched cases (8/8).

40 received an allogeneic HCT with four of six HLA-matched CCR5 Delta32 homozygous cord blood cells (St

41 is considered a future clinical strategy for HLA-matched cell transplantation to reduce immunological

42 sorbent spot assays with pools of predicted, HLA-matched, class I binding peptides covering the entir

43 lity in a training subset (n = 1,151) of the HLA-matched cohort.

44 sed tetramer(+) CD4(+) T cells compared with HLA-matched control subjects without diabetes.

45 -A*24(+) recent-onset patients compared with HLA-matched control subjects.

46 some people with recent-onset T1D but not in HLA-matched control subjects.

47 Treatment of EBV-associated PTLD with partly HLA-matched CTLs grown from unrelated donors is effectiv

48 91%) compared with children receiving a well HLA-matched DBD kidney transplant (83%, 95% CI, 80-86%,

49 stify preferentially waiting for an improved HLA-matched DBD kidney when a poorer HLA-matched LD kidn

50 mes are not inferior when compared with well HLA-matched DBD renal transplants.

51 For patients without an available HLA matched donor, the use of 2 partially HLA-matched UC

52 ihoods of finding a human leukocyte antigen (HLA)-matched donor for patients of various racial/ethnic

53 easible alternative for patients who lack an HLA-matched donor and can now be applied to treat patien

54 ion is limited by availability of a suitable HLA-matched donor and lack of awareness of the benefits

55 onmyeloablative regimen followed by combined HLA-matched donor bone marrow and renal allotransplantat

56 stem cell transplantation (AlloSCT) utilizes HLA-matched donor bone marrow or peripheral blood stem c

57 ers can improve the likelihood of finding an HLA-matched donor, but will still leave significant numb

58 For patients without a suitable related HLA-matched donor, unrelated-donor registries of adult v

59 y and hematopoietic-cell transplants from an HLA-matched donor.

60 er-small bowel transplantation from a 1-of-6 HLA-matched donor.

61 in each of the eight HLA-mismatched and one HLA-matched donor/recipient pairs.

62 31 patients had HLA matched donors who were related and 18 had donors wh

63 uable strategy for identifying more suitably HLA-matched donors and has the potential for alleviating

64 ation can cure sickle cell disease; however, HLA-matched donors are difficult to find, and the toxici

65 atopoietic progenitor cells and T cells from HLA-matched donors in a tolerance induction protocol.

66 ents should receive granulocytes from either HLA-matched donors or donors selected by leukoagglutinat

67 ransplanted within 1 year of diagnosis using HLA-matched donors who had 63% (95% CI, 53%-73%) DFS at

68 HLA typing, should be performed to identify HLA-matched donors with B KIR haplotypes.

69 Fifty-seven HLA-matched donors, 12 HLA-mismatched donors, and 1 CD3(

70 The best outcomes have been achieved with HLA-matched donors, but when a matched donor is not avai

71 n successfully performed in patients with no HLA-matched donors, leukemia caused by vector-mediated i

72 a show that the outcome of HSCT for SCN from HLA-matched donors, performed in recent years, in patien

73 Better HLA-matched donors, use of bone marrow, and transplantat

74 to children with major SCD complications and HLA-matched donors.

75 n (BMT) is a therapeutic option but requires HLA-matched donors.

76 xpands the use of allotransplantation to non-HLA-matched donors.

77 GVHD after bone marrow transplantation from HLA-matched donors.

78 nrelated adult donor (MMUD, n = 52) or 4-6/6 HLA matched dUCB (n = 128) graft after myeloablative con

79 fusion of partially human leukocyte antigen (HLA)-matched EBV-specific CTL grown ex vivo from an EBV

80 Ls produced infectious virus when exposed to HLA-matched EBV-expressing targets, but not on exposure

81 of testing a total of 199 embryos, 45 (23%) HLA-matched embryos were selected, of which 28 were tran

82 We investigated the use of non-HLA-matched ex-vivo expanded cord blood progenitor cells

83 t of the study was safety of infusion of non-HLA-matched expanded cord blood progenitor cells after a

84 not have a suitable human leukocyte antigen (HLA)-matched family donor, unrelated donor registries of

85 tients with severe PNH underwent HCT from an HLA-matched family donor after conditioning with cycloph

86 bone-marrow transplantation is successful if HLA-matched family donors are available, but HLA-mismatc

87 Although HLA matched genotypically, there may be differences in a

88 ter randomisation, patients either receive a HLA-matched graft (experimental intervention) or a rando

89 3; P=0.001); the risk was also higher in the HLA-matched group than in the cord-blood group but not s

90 I, 0.76 to 2.46; P=0.30; hazard ratio in the HLA-matched group, 0.78; 95% CI, 0.48 to 1.28; P=0.33).

91 I, 0.51 to 3.25; P=0.60; hazard ratio in the HLA-matched group, 1.30; 95% CI, 0.65 to 2.58; P=0.46).

92 I, 1.22 to 7.38; P=0.02; hazard ratio in the HLA-matched group, 2.92; 95% CI, 1.34 to 6.35; P=0.007).

93 nts of histocompatibility leukocyte antigen (HLA)-matched, HA-1-mismatched renal transplants, one of

94 mic relapse, but capturing alloreactivity in HLA-matched HCT has been elusive.

95 In clinical settings, HLA-matched HCT is preferred to facilitate engraftment a

96 1-mediated inhibition in donor selection for HLA-matched HCT may achieve superior graft versus leukem

97 125 cord blood, 125 HLA-mismatched, and 154 HLA-matched HCTs, detection of multiple viruses was comm

98 measured by an IFN-gamma T cell response in HLA-matched HCV-infected individuals.

99 ween Type 1 diabetes patients and age/gender/HLA-matched healthy adults.

100 ng in 5 singleton pregnancies and birth of 5 HLA-matched healthy children.

101 When considering HLA-matched hematopoietic cell transplantation (HCT), si

102 These results demonstrate that a majority of HLA-matched hematopoietic cell transplantations involve

103 panded donor natural killer (NK) cells after HLA-matched hematopoietic stem cell transplantation (HSC

104 r did not persist in the plasma of their non-HLA-matched HIV-1-infected infants.

105 Studies in HLA-matched HSCT, however, have also demonstrated improv

106 confirm that NK alloreactivity can occur in HLA-matched HSCT, where tolerance to self is either acqu

107 eneic HSCT and was suggested not to occur in HLA-matched HSCT.

108 ng memory CD8(+) T cell clones, we looked in HLA-matched IM patients and found such reactivities but

109 cold ischemia justifies national sharing of HLA-matched kidney transplants.

110 was superior for children receiving a poorly HLA-matched LD kidney transplant (88%, 95% confidence in

111 mproved HLA-matched DBD kidney when a poorer HLA-matched LD kidney transplant is available.

112 In children, poorly HLA-matched LD renal transplant outcomes are not inferio

113 o cytotoxic and can control the outgrowth of HLA-matched lymphoma cells in cocultivation assays.

114 and secreted interferon-gamma in response to HLA-matched melanocytes and cultured lymphangioleiomyoma

115 ponsive T cells were reacted with pretreated HLA-matched melanoma cells.

116 cific T cells were cytotoxic toward gp100(+) HLA-matched melanoma targets, but not HLA-mismatched mel

117 ell responses after human leukocyte antigen (HLA)-matched, mHag-mismatched stem-cell transplantation.

118 and the risk of chronic GVHD associated with HLA-matched mobilized blood cell grafts can be substanti

119 -risk MM patients receiving allo-SCT from an HLA-matched (n = 14) or mismatched (n = 2) sibling follo

120 8 years received a marrow transplant from an HLA-matched (n = 56) or partly matched (n = 32) unrelate

121 lood were transplanted with grafts that were HLA-matched (n=35) or HLA-mismatched for one (n=201) or

122 evaluate the safety and efficacy of sibling, HLA-matched, nonmyeloablative allogeneic SCT with donor

123 ng couples with a realistic option of having HLA-matched offspring to serve as potential donors of st

124 2, were cocultured with responder cells from HLA-matched or -mismatched donors.

125 These CD4+ T cells recognize NY-ESO-1(+), HLA-matched or autologous melanoma cell lines, as well a

126 st candidates for HSCT will have a suitable (HLA-matched or minimally mismatched) adult donor.

127 npermissive HLA-DPB1 mismatches in otherwise HLA-matched pairs is indicated.

128 ne +/- TBI), and 8 of 8 (n = 313) and 7 of 8 HLA-matched PBPCs (n = 111).

129 od donors were tested for reactivity against HLA-matched peptides by using gamma interferon enzyme-li

130 ymocyte globulin, followed by an infusion of HLA-matched peripheral-blood mononuclear cells from rela

131 sfusions because of alloimmunization require HLA-matched platelets, which is only possible if a large

132 ailability and selection of crossmatched and HLA-matched platelets.

133 l strategy for prioritizing among comparably HLA-matched potential donors has not been established.

134 KIR genotyping of several best HLA-matched potential unrelated donors should substantia

135 nd confers specific cytotoxicity against KIR/HLA-matched PSCA-positive tumor cells, which was further

136 Rapid disease progression is observed in HLA-matched recipients to whom mutated virus is transmit

137 a shorter cold ischemia time to more poorly HLA-matched recipients.

138 antation (HCT) from human leukocyte antigen (HLA) matched related donor (MRD) and matched unrelated d

139 Use of human leukocyte antigen (HLA)-matched related (MR) peripheral blood stem cells co

140 splantation with an human leukocyte antigen (HLA)-matched related donor (MRD, n = 204), HLA allele-ma

141 to lack of a fully human leukocyte antigen (HLA)-matched related donor.

142 alignancies; 78 had human leukocyte antigen (HLA)-matched related donors and 39 had HLA-matched unrel

143 -agent GVHD prophylaxis after myeloablative, HLA-matched related (MRD), or HLA-matched unrelated (MUD

144 We carried out HLA-matched related (n = 16) and unrelated (n = 17) hema

145 ral blood stem-cell (n = 18) transplant from HLA-matched related (n = 18) or unrelated (n = 2), or 1

146 syngeneic (n = 2) HCT and were treated with HLA-matched related (n = 62) or unrelated (n = 85) graft

147 Our study indicates that HLA-matched related BMT is an effective treatment for pe

148 here is considerable variation in the use of HLA-matched related bone marrow transplantation (BMT) fo

149 topoietic cell transplantation (HCT) have an HLA-matched related donor (MRD) available to them.

150 In multivariate analysis, HLA-matched related donor and prophylaxis with cyclospor

151 ntation with haemopoietic stem cells from an HLA-matched related donor does not seem to improve the c

152 oablative and 73 myeloablative recipients of HLA-matched related donor HCT, using the National Cancer

153 Younger patients and recipients of HLA-matched related donor transplantations who have cyto

154 an allogeneic stem cell transplant from her HLA-matched related donor.

155 nsplantation and had an available 8/8 or 7/8 HLA-matched related donor.

156 In transplantations from HLA-matched related donors (n = 82), younger patients (<

157 ogic malignancies who were given grafts from HLA-matched related donors following conditioning with 2

158 gnancies undergoing TCD transplantation from HLA-matched related donors without the use of ATG.

159 T) to bone marrow transplantation (BMT) from HLA-matched related donors, we found no statistically si

160 ed 17, 14 from HLA-haploidentical and 3 from HLA-matched related donors.

161 osuppression after nonmyeloablative HCT with HLA-matched related grafts.

162 I haplotype also occurs in AML relapse after HLA-matched related HSCT.

163 Even transplantation with stem cells from HLA-matched related or HLA-matched unrelated donors tend

164 against graft-versus-host disease (GVHD) in HLA-matched related or unrelated allogeneic hematopoieti

165 ts given hematopoietic cell transplants from HLA-matched related or unrelated donors after conditioni

166 Patients with HLA-matched related or unrelated donors had similar surv

167 e age of 10 years, in recent years, and from HLA-matched related or unrelated donors were associated

168 ng factor (G-CSF)-mobilized blood cells from HLA-matched related or unrelated donors.

169 = 135) or RIC (n = 137) followed by HCT from HLA-matched related or unrelated donors.

170 orts of patients having the same donor type (HLA-matched related, unrelated, or both) reported in the

171 21 HLA-matched related-donor and 35 HLA-matched unrelated-d

172 e marrow or peripheral blood stem cells from HLA-matched related-donors or HLA-9/10 or HLA-10/10 matc

173 hylaxis after myeloablative conditioning and HLA-matched-related or -unrelated T-cell-replete allogra

174 donor cells/kg); the donor was the patient's HLA-matched, rheumatoid factor-negative sister.

175 survival similar to those of contemporaneous HLA-matched RIC HSCT at our institution.

176 reatment-related mortality (P < .001) in the HLA-matched set and relapse (P < .001) in the HLA-mismat

177 riteria as are currently used for those with HLA matched sibling donors.

178 Human leukocyte antigen (HLA)-matched sibling donor (MSD) HSCT remains the gold s

179 -five patients with human leukocyte antigen (HLA)-matched sibling donors underwent T-cell-depleted al

180 ly) obtained from a human leukocyte antigen (HLA)-matched sibling.

181 There were 811 HLA-matched sibling (61%) and 522 (39%) unrelated donor

182 We compared these results with HLA-matched sibling (matched sibling donors [MSDs]) BMT

183 d unrelated donor (MUD) rather than an older HLA-matched sibling (MSD).

184 Donors were HLA-matched sibling (n = 1), HLA-matched unrelated (n =

185 onstrated superior 5-year outcome after auto/HLA-matched sibling allo HSCT compared with tandem auto

186 dictive for survival by using data from 1827 HLA-matched sibling allotransplant recipients reported t

187 abilities of survival were 62% and 62% after HLA-matched sibling and 42% and 39% after alternative do

188 of death, accounting for 50% of deaths after HLA-matched sibling and 43% of deaths after alternative

189 cidence of neutrophil recovery was 66% after HLA-matched sibling and 61% after alternative donor tran

190 eukemia-free survival were 49% and 54% after HLA-matched sibling and unrelated donor transplantation

191 sults suggest that allogeneic HSCT from both HLA-matched sibling and unrelated donors can induce dura

192 ars of age with class 3 thalassemia received HLA-matched sibling BMT following either the original pr

193 atologic relapse of myeloid malignancy after HLA-matched sibling BMT were prospectively treated with

194 Allogeneic bone marrow transplant from an HLA-matched sibling can halt disease progression but is

195 Long-term survival was higher after HLA-matched sibling compared to alternative donor transp

196 EFS after HLA-matched sibling donor (MSD) and 6/6 matched unrelate

197 utcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelate

198 hat the majority of children with a suitable HLA-matched sibling donor can expect a cure from this ap

199 rce, disease risk, age, and transplant year, HLA-matched sibling donor marrow resulted in the best GR

200 n the best GRFS (51%, 95% CI 46-66), whereas HLA-matched sibling donor peripheral blood stem cells we

201 Among HLA-matched sibling donor transplantation recipients, th

202 These data support HLA-matched sibling donor transplantation using a TBI-co

203 s hematopoietic stem cell transplant from an HLA-matched sibling donor, although <25% of patients hav

204 c hematopoietic cell transplant will have an HLA-matched sibling donor.

205 roup) on the basis of the availability of an HLA-matched sibling donor.

206 unfavorable cytogenetics who lack a suitable HLA-matched sibling donor.

207 bilized, unmanipulated stem cells from a 6/6 HLA-matched sibling donor.

208 myeloma and end-stage renal disease with an HLA-matched sibling donor; the second for patients with

209 ts in first CR (28% versus 3%, P =.008), and HLA-matched sibling donors (81% versus 40%, P =.001).

210 those of transplantation using conventional HLA-matched sibling donors (MRDs) and HLA-matched unrela

211 Cy) is increasingly used in patients lacking HLA-matched sibling donors (MSD).

212 and the remainder received bone marrow from HLA-matched sibling donors for predominantly high-risk h

213 Sixty-seven patients with HLA-matched sibling donors received fractionated total b

214 ted allogeneic SCT, and 137 patients without HLA-matched sibling donors underwent autologous SCT.

215 Allografts from HLA-matched sibling donors were mobilized and collected

216 Most likely to benefit are patients who have HLA-matched sibling donors, are in remission, and have g

217 no difference was seen in patients receiving HLA-matched sibling grafts.

218 Thus, in HLA-matched sibling HSCT for myeloid leukemia, patients

219 determined in 220 donor-recipient pairs from HLA-matched sibling HSCTs performed for myeloid (n = 112

220 GVH-mismatched unrelated recipients than in HLA-matched sibling recipients.

221 oderate/severe) in parallel analyses of 1092 HLA-matched sibling transplant recipients from the IBMTR

222 efforts to further accelerate engraftment in HLA-matched sibling transplants by increasing CD34 cell

223 ents enrolled in chemotherapy trials and 186 HLA-matched sibling transplants, treated between 1991 an

224 received T-cell-replete bone marrow from an HLA-matched sibling.

225 s were primarily peripheral blood (77%) from HLA-matched siblings (40%) or well-matched unrelated don

226 hematopoietic stem cells were obtained from HLA-matched siblings (n = 4) and unrelated donors (n = 4

227 CD4(+) T cells in 32 donor SCTs infused into HLA-matched siblings and examined GVHD incidence in resp

228 expansion of potent mHA-specific Tregs from HLA-matched siblings in sufficient numbers for applicati

229 imulated by dendritic cells (DCs) from their HLA-matched siblings in the presence of interleukin 2, i

230 eral blood stem cell (PBSC) transplants from HLA-matched siblings were compared.

231 Patients <or= age 55 with HLA-matched siblings were prioritized toward allo BMT.

232 four percent of transplants used grafts from HLA-matched siblings, 13% from HLA-mismatched relatives,

233 s to safely undergo BMT from RDs who are not HLA-matched siblings, with transplant outcomes similar t

234 ing factor (G-CSF), which were obtained from HLA-matched siblings.

235 s who underwent non-T-cell-depleted BMT from HLA-matched siblings.

236 After HLA-matched stem cell transplantation, KIR repertoires e

237 s the time constraint of urgent provision of HLA-matched stem cells for a sick sibling.

238 contained small, undetectable, EBV-specific, HLA-matched T cell populations or perhaps they stimulate

239 -1BBL-activated NK cells (aNK-DLI) following HLA-matched, T-cell-depleted (1-2 x 10(4) T cells/kg) no

240 with the frequency of T cells reactive to an HLA-matched third party.

241 ct and transfer only those embryos that were HLA matched to affected siblings.

242 rom young donors (aged 18-32 years) who were HLA matched to recipients (P < .001).

243 +) T cells capable of killing LCLs that were HLA matched to the DCs.

244 recipients of units closely (7-10 to 10-10) HLA-matched to each other were more likely to demonstrat

245 I expression may be an alternative to fully HLA-matched transfusions.

246 Eighteen leukemia patients undergoing HLA-matched transplantation and their donors were analyz

247 Compared with HLA-matched transplantations, mortality was higher with

248 acute GVHD occurred in 43% of patients given HLA-matched transplants and in 59% given partly matched

249 ar rate of graft survival was 52 percent for HLA-matched transplants, as compared with 37 percent for

250 receptor had demonstrably higher signals in HLA-matched tumors compared with those in animals that r

251 we did not observe any responses against non-HLA-matched tumors, and no killing of any kind occurred

252 use of 2 partially human leukocyte antigen (HLA)-matched UCB units, or double UCB graft, to meet the

253 tion of 2 partially human leukocyte antigen (HLA)-matched UCB units.

254 The transplantation of 2 partially HLA-matched UCB units has been adopted as a simple appro

255 le HLA matched donor, the use of 2 partially HLA-matched UCB units is a suitable alternative.

256 Therefore, transplantation of 2 partially HLA-matched UCB units is safe, and may overcome the cell

257 e II acute GVHD in recipients of 2 partially HLA-matched UCB units, there is no adverse effect on TRM

258 ients after transplantation with 2 partially HLA-matched UCB units.

259 All patients received >/=4 antigens HLA-matched UCBT.

260 ens and possibly higher after transplants of HLA-matched umbilical cord blood.

261 r 2 (53%) partially human leukocyte antigen (HLA)-matched unit(s).

262 Compared with HLA-matched units, neutrophil recovery was lower with mi

263 ed at 1, 2, 3, 4, or 5 alleles compared with HLA-matched units.

264 out whether a male human leukocyte antigen (HLA)-matched unrelated donor (MUD, 8/8, n=2,014) might b

265 Donors were sibling (n = 75) or HLA-matched unrelated (10/10; n = 88).

266 myeloablative, HLA-matched related (MRD), or HLA-matched unrelated (MUD) donor T-cell-replete bone ma

267 Donors were HLA-matched sibling (n = 1), HLA-matched unrelated (n = 9), HLA-mismatched unrelated

268 adults with acute leukaemia when there is no HLA-matched unrelated adult donor available, and when a

269 nrelated cord-blood donor (140 patients), an HLA-matched unrelated donor (344), or an HLA-mismatched

270 en undergoing HSCT from an MRD (n = 4) or an HLA-matched unrelated donor (MUD) (n = 7); 9 children we

271 SAA patients younger than 40-50 years, with HLA-matched unrelated donor (MUD) HSCT for second line a

272 be improved with a younger allele-level 8/8 HLA-matched unrelated donor (MUD) rather than an older H

273 entional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD).

274 (AML) after haploidentical (n = 192) and 8/8 HLA-matched unrelated donor (n = 1982) transplantation.

275 ) donor were similar at 81%, 66% after 10/10 HLA-matched unrelated donor (UD), and 68% after 5/6 matc

276 nts who received haploidentical (n = 185) or HLA-matched unrelated donor (URD) transplantation either

277 s that after receipt of a transplant from an HLA-matched unrelated donor and was significantly higher

278 We have carried out HLA-matched unrelated donor hematopoietic cell transplan

279 igen-matched sibling, 884 from a 7 or 8 of 8 HLA-matched unrelated donor.

280 tional HLA-matched sibling donors (MRDs) and HLA-matched unrelated donors (MUDs).

281 HLA-DPB1 alleles in patients and their 10/10 HLA-matched unrelated donors of 379 HCTs performed at ou

282 with stem cells from HLA-matched related or HLA-matched unrelated donors tended to be associated wit

283 ated from HLA-genoidentical siblings or from HLA-matched unrelated donors who were identified and mat

284 emia, or myelodysplastic syndrome, and their HLA-matched unrelated donors, reported to the Center for

285 n be achieved with HLA-identical related and HLA-matched unrelated donors, respectively.

286 ith AML who underwent HCT from 9/10 or 10/10 HLA-matched unrelated donors.

287 ogenitor cells (PBPCs) from 8 of 8 or 7 of 8 HLA-matched unrelated donors.

288 igen (HLA)-matched related donors and 39 had HLA-matched unrelated donors.

289 the clinical results of transplantation from HLA-matched unrelated donors.

290 plastic syndrome who underwent myeloablative HLA-matched unrelated hematopoietic cell transplantation

291 s of PTLD comparable to those reported after HLA-matched unrelated marrow myeloablative (MA) transpla

292 were KIR mismatched and 3 were matched; all HLA-matched unrelated pairs were KIR mismatched.

293 Among HLA-matched unrelated pairs, the patient's IL10/-592 gen

294 es in survival after HLA-mismatched related, HLA-matched unrelated, or mismatched unrelated donor tra

295 and 2 Gy total body irradiation followed by HLA-matched unrelated-donor HCT and postgrafting cyclosp

296 21 HLA-matched related-donor and 35 HLA-matched unrelated-donor transplants were done.

297 eive myeloablative HCT from an available 8/8-HLA matched URD.

298 e considered when selecting among comparably HLA-matched volunteer donors.

299 When several comparably HLA-matched volunteers are identified for a patient, var

300 Sixteen percent of units were HLA-matched with the recipient, whereas 43% and 35% had